Last reviewed · How we verify

NCT07344168

EndoArt® Implantation in Subjects With Chronic Corneal Edema - US Study

Not yet recruiting NA Last updated 13 March 2026
What this trial tests

NA trial testing The EndoArt® (Corneal Artificial Endothelial layer) in Corneal Edema in 123 participants. Not yet recruiting.

Timeline
1 May 2026
Primary endpoint
30 April 2029
30 April 2030

Quick facts

Lead sponsorEye-yon Medical
PhaseNA
StatusNot yet recruiting
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposetreatment
Enrollment123
Start date1 May 2026
Primary completion30 April 2029
Estimated completion30 April 2030

Drugs / interventions tested

Conditions studied

Sponsor

Eye-yon Medical — full company profile →

Who can join

Adults 35 to 85, any sex, with Corneal Edema. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The EndoArt® device is intended to treat patients with chronic corneal edema due to endothelial dysfunction, in whom prior multiple keratoplasty (EK/PK) have failed, and who are not reasonable candidates for any form of corneal transplant, including penetrating keratoplasty. The EndoArt® (Corneal Artificial Endothelial layer) is a permanent synthetic implant. It is made of a clear, transparent, foldable, biologically compatible hydrophilic copolymer. The device serves as an inert physical barrier, blocking the ingress of fluid from the Anterior Chamber (AC) into the cornea.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Corneal Edema

Currently open trials in the same condition.

Other Eye-yon Medical trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07344168.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing